Covestro medical-grade Makrolon® polycarbonate utilized for breakthrough wound healing device
Potential to transform wound healing
Vaporox’s Vaporous Hyperoxia Therapy (VHT®) technology is clinically validated for healing skin wounds. A combination of Covestro resin and technical support helps bring next-generation wound care medical device to market.
Chronic wounds afflict millions of people. If not treated adequately, they can lead to severe complications, including amputation of limbs. Denver-based Vaporox developed a medical device for healing chronic wounds that do not respond to conventional wound treatment. The vaporizer component of the medical device primarily utilizes Makrolon® 2458 polycarbonate from Covestro.
The VHT-200 (Vaporous Hyperoxia Therapy™) system, which received U.S. Food and Drug Administration (FDA) clearance, features a unique combination of elements that accelerate healing—ultrasonic vapor and concentrated oxygen. According to Vaporox, the patented delivery system for these elements promotes revascularization and tissue growth. The treatment is intended for administration in clinics and physicians’ offices.
“Vaporox is committed to a world where all wounds heal,” said Chase Huskey, marketing manager, Vaporox. “Today, wound care is one of the most under-served markets in the medical industry, but this development is truly life-changing for patients and a huge step forward for this market.”
Covestro was involved throughout the device’s development, supplying prototype quantities of its material, and documentation required by the FDA.
Makrolon® 2458 polycarbonate is a low-viscosity, injection-molding medical grade that features easy release from the mold. It is suitable for Ethylene Oxide (EtO) and steam sterilization and is biocompatible according to many ISO 10993-1 test requirements. It is available in transparent and opaque options.
“For decades, the healthcare market has relied on our proven portfolio of medical grade Makrolon® polycarbonates, complemented by customized technical expertise,” said Mark Nichols, healthcare key account manager, Covestro LLC. “Our work with Vaporox demonstrates the value of collaboration as our customers develop and bring truly innovative, game-changing technology to market.
Attendees at MD&M West, February 6-8 in Anaheim, California, can visit the Covestro booth (#2221) to learn how the company’s materials push boundaries in healthcare applications.
Covestro is one of the world’s leading manufacturers of high-quality polymer materials and their components. With its innovative products, processes and methods, the company helps enhance sustainability and the quality of life in many areas. Covestro supplies customers around the world in key industries such as mobility, building and living, as well as the electrical and electronics sector. In addition, polymers from Covestro are also used in sectors such as sports and leisure, cosmetics and health, as well as in the chemical industry itself.
The company is committed to becoming fully circular and is striving to become climate neutral by 2035 (scope 1 and 2). Covestro generated sales of EUR 18 billion in fiscal 2022. At the end of 2022, the company had 50 production sites worldwide and employed approximately 18,000 people (calculated as full-time equivalents).
Makrolon® is a registered trademark of Covestro Group. VHT® is a registered trademark of Vaporox, Inc.
This news release may contain forward-looking statements based on current assumptions and forecasts made by Covestro AG. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Covestro’s public reports which are available at www.covestro.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
Follow news from Covestro on Twitter: https://twitter.com/CovestroUS